HUTCHMED (LSE:HCM) said its partner AstraZeneca submitted a New Drug Application to the US Food and Drug Administration on 29 September 2026 for ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib). The filing targets a subset of lung cancer patients whose disease has progressed after EGFR tyrosine kinase inhibitor treatment.
What was announced
HUTCHMED (China) Limited, which is quoted on AIM and Nasdaq under the ticker LSE:HCM and on the Hong Kong exchange under code 13, announced that AstraZeneca has filed a New Drug Application (NDA) with the FDA for the combination of ORPATHYS and TAGRISSO.
The proposed indication is locally advanced or metastatic non-small cell lung cancer (NSCLC) with MET overexpression or amplification, in patients whose disease has progressed following EGFR-TKI therapy. ORPATHYS is jointly developed by AstraZeneca and HUTCHMED and is commercialised by AstraZeneca.
The submission marks the start of the US regulatory review process; it is not an approval. The announcement does not give a Prescription Drug User Fee Act (PDUFA) target action date, a review timeline, or whether priority review has been requested. It also does not disclose any milestone payment or other financial consequence for HUTCHMED arising from the filing.
The trial data
The NDA is primarily supported by SAFFRON, a randomised, open-label, multi-centre global Phase III study conducted across 230 centres in 29 countries. It enrolled 338 patients with EGFR-mutated, locally advanced or metastatic NSCLC with MET overexpression or amplification whose disease had progressed on first- or second-line TAGRISSO.
Patients received ORPATHYS at 300mg twice daily plus TAGRISSO at 80mg once daily, compared with doublet platinum-based chemotherapy. The primary endpoint was progression-free survival (PFS), with overall survival (OS) as a key secondary endpoint.
According to the announcement, the study demonstrated a "statistically significant and clinically meaningful improvement in both progression-free survival and overall survival" versus chemotherapy, with a safety profile consistent with known data and no new safety concerns. Hazard ratios and median survival figures were not disclosed; the company said the results will be presented in a Presidential Symposium at the ESMO Congress 2026.
The filing is also supported by two earlier studies. The SACHI Phase III trial underpinned approval of the combination in China in a similar patient population, and the SAVANNAH Phase II trial identified high MET-level cut-offs using immunohistochemistry (IHC) and fluorescence in situ hybridisation (FISH) testing to select patients.
Background
ORPATHYS is an oral, highly selective MET tyrosine kinase inhibitor designed to block atypical activation of the MET receptor caused by mutations, gene amplification or protein overexpression. In China it is approved for NSCLC with MET exon 14 skipping alterations, holds conditional approval in certain MET-amplified gastric and gastroesophageal junction cancers after at least two prior treatments, and is approved in combination with TAGRISSO for EGFR-mutated NSCLC with MET amplification after EGFR-TKI progression. Switzerland has granted temporary authorisation for the combination based on SAVANNAH.
The announcement cites estimates that MET overexpression or amplification develops in around 34% of tumours after progression on a third-generation EGFR-TKI, and that EGFR-mutated disease accounts for 10-15% of NSCLC in the US and Europe and 30-40% in Asia.
Johnny Cheng, Acting Chief Executive Officer and Chief Financial Officer, said: "This filing is an important step toward potentially bringing ORPATHYS plus TAGRISSO to patients in the US, after its approval in China based on the SACHI Phase III trial."
What to watch next
The next scheduled event identified in the announcement is the presentation of full SAFFRON results at ESMO 2026, where the company has said the results will be presented; hazard ratios and survival data were not included in this release. Further updates would be needed on FDA acceptance of the filing and any target action date. The outcome of the US review is not known, and approval is not assured.
_11_19_2026_14_04_21_792016.jpg)
_11_19_2026_14_04_28_358813.jpg)




Please wait processing your request...